Johnson & Johnson
Analysis Result: 5 out of 5 MUMAKS
Rating
This analysis evaluates Johnson & Johnson according to the UMBRELLA strategy using the MUMAK method.
The valuation is conducted across five decision-making phases: Geopolitics, Industry, Fundamentals, Market Sentiment, and Technical Analysis.
The goal is not to predict the future precisely. The goal is orientation. We contextualize facts, demonstrate causal relationships, and structure a comprehensible decision logic.
We explain – you decide.
Geopolitics
Classification
The geopolitical and demographic environment remains broadly supportive for large healthcare groups. An ageing global population, rising healthcare spending and persistently strong demand for innovative therapies are strengthening Johnson & Johnson’s long-term growth outlook. At the same time, pricing pressure, regulatory intervention and government cost-cutting programmes remain structural challenges.
Key Takeaway
- The ageing global population is driving structurally rising demand over the long term for oncology, cardiovascular, immunology and surgical treatments.
- Demand for healthcare services remains comparatively stable even in weaker economic phases.
- Oncology and immunology remain among the most attractive global growth areas.
- Healthcare policy measures in the US and Europe can create pricing and reimbursement pressure.
- Stable and resilient supply chains remain highly important for pharmaceutical and medical technology manufacturers.
Johnson & Johnson perfectly embodies these core points and offers solutions to a range of emerging challenges. As a globally active group with history and experience, it appears to be an anchor in healthcare.
MUMAK.me Assessment Phase 1: Positive = 1 MUMAK
Johnson & Johnson
Geopolitics Rating: positive
Industry
Assessment
The healthcare sector remains one of the most attractive long-term growth industries worldwide. Innovation, demographic change, the growing importance of modern cancer therapies and technological progress in medical technology support industry growth. Johnson & Johnson benefits from its broad diversification between Innovative Medicine and MedTech. However, patent expiries and litigation remain key industry-specific risks.
Valuation Comparison: Johnson & Johnson vs. Healthcare and Pharmaceutical Industry
| Key Figure | Johnson & Johnson | Industry average* | Premium / Discount |
|---|---|---|---|
| P/E Ratio | 22.0x | ~22–24x | Nearly at industry level |
| EV/EBITDA | 17.7x | 15.0–18.0x | Slight premium |
| Dividend Yield | 2,2 % | ~2.0–2.5% | At industry level |
Peer group: Roche, Merck, Novartis, AstraZeneca, Abbott and AbbVie. Source: MarketScreener, July 2026.
Key Takeaway
- Johnson & Johnson remains one of the world’s leading healthcare groups.
- Diversification between pharmaceuticals and medical technology reduces dependence on individual products.
- Growth products in oncology and immunology are expected to offset the patent expiry of Stelara.
- Valuation is not cheap, but is supported by high quality and strong cash flows.
- Patent expiries and pricing pressure in healthcare remain key risk factors.
MUMAK.me Evaluation Phase 2: positive = 1 MUMAK
Johnson & Johnson
Industry Rating: neutral
Fundamentals
Assessment
Johnson & Johnson combines stable revenue growth with high profitability and one of the strongest balance sheets in the healthcare sector. The company consistently generates high free cash flows, funding dividends, acquisitions, share buybacks and investments in research and development.
Key figures
| Key Figure | FY 2024 | FY 2025 | FY 2026e |
|---|---|---|---|
| Revenue | USD 88.8 billion | USD 94.2 billion | USD 100.9 billion |
| Revenue Growth | approx. 4% | approx. 6% | approx. 7% |
| EBITDA | USD 31.3 billion | USD 33.8 billion | USD 37.1 billion |
| EBITDA Margin | approx. 35% | approx. 36% | approx. 37% |
| Free Cash Flow | USD 18.0 billion | USD 17.2 billion | USD 18–20 billion |
| Diluted EPS | USD 9.98 | USD 10.80 | USD 11.00–11.20 |
Source: MarketScreener / company data, July 2026.
Key Takeaway
- Revenue growth remains stable and highly predictable for a large healthcare group.
- The profitability remains among the highest in the industry.
- Free cash flow of more than USD 17 bn provides high financial flexibility.
- Moderate net debt enables further acquisitions and investments in research and development.
- Johnson & Johnson has increased its dividend for more than 60 years without interruption.
MUMAK.me Assessment Phase 3: Positive = 1 MUMAK
Johnson & Johnson
Fundamentals Rating: positive
News, Analysts, and Market Sentiment
Assessment
Overall market sentiment remains positive, supported by the defensive business model, the broadly diversified product portfolio and the strong pharma pipeline.
Johnson & Johnson is consistently pursuing its long-term growth strategy and continues to invest selectively in innovation and complementary acquisitions. The announced acquisition of Firefly Bio strengthens the oncology pipeline in particular and expands the technology platform in the field of Degrader Antibody Conjugates (DAC). At the same time, the MedTech business continues to develop positively, with progress in cardiovascular and surgical technologies. Investors’ focus is now on the quarterly results on July 15, 2026, which will provide further indications on growth in the most important products, margin development and management’s outlook.
Analyst Consensus
| Average Consensus | ACCUMULATE |
| Number of Analysts | 23 |
| Average Price Target | approx. USD 258 |
| Upside to the average target | ~ +11% |
| Highest price target | USD 290 |
| Lowest Price Target | USD 180 |
Source: MarketScreener, as of July 2026.
Interesting Fact
With the acquisition of Firefly Bio, Johnson & Johnson gains access to the innovative Firelink™ technology for so-called Degrader Antibody Conjugates (DAC), a new platform for developing future cancer therapies and further strengthening the long-term innovation strategy.
Key Takeaway
- Strategic investments strengthen the oncology pipeline over the long term.
- Innovative Medicine and MedTech remain the group’s two central growth pillars.
- The quarterly results in July are the next important price catalyst.
- Strong cash flows and a robust balance sheet support the long-term investment case despite legal and patent risks.
MUMAK.me Evaluation Phase 4: Positive = 1 MUMAK
Johnson & Johnson
Market Sentiment Rating: positive
Technical Analysis
Assessment
The technical picture for Johnson & Johnson has improved significantly in recent weeks. After the correction in April and May, the stock was able to stabilise above the key support zone between USD 228 and USD 241 and resume the broader uptrend.
The latest breakout above the previous sideways range pushed the price up to the key resistance area around USD 263, which currently marks the relevant high. Rising moving averages, increasing momentum and improved momentum indicators point to a constructive overall technical picture. However, after the strong upward move, the stock is approaching an overbought situation in the short term.
Key Takeaway
- The medium- and long-term uptrend remains intact.
- The breakout above the previous consolidation confirms this.
- The area around USD 263 currently represents the most important resistance.
- A sustained breakout above USD 263 could open up further upside potential.
- The support zone between USD 240 and USD 242 remains the most important short-term safeguard.
RSI (14)
Slightly bullish
- Current RSI: approx. 68
- Approaching the overbought zone (70), but not yet overbought
- The RSI has recovered significantly since the correction in April/May
Interpretation: Slightly bullish. The stock shows good momentum, but is already moving toward a short-term overbought situation.
MACD (12/26/9)
Strongly positive
- The MACD is trading well above the signal line.
- Both MACD and signal line continue to rise.
- The breakout has further strengthened the bullish momentum.
Interpretation: The MACD confirms an intact uptrend and suggests a continuation of the positive price development.
Bollinger Bands (20)
Bullish
- The price is trading near the upper Bollinger Band.
- The middle Bollinger Band continues to rise.
- The recent breakout is confirmed by the current price development.
Interpretation: Trading near the upper Bollinger Band indicates sustained buying pressure.
MUMAK.me Assessment Phase 5: Positive = 1 MUMAK
Johnson & Johnson
Technical Analysis Rating: positive
What currently speaks in favor of Johnson & Johnson?
- Globally aging population ensures sustainable demand growth.
- Leading positions in oncology, immunology, and neuroscience.
- Diversified business model comprising pharmaceuticals and medical technology.
- High free cash flows and very strong balance sheet.
- Dividend aristocrat with over 60 consecutive dividend increases.
- Continuous pipeline progress and targeted acquisitions.
What currently speaks against it?
- Patent expirations, particularly for Stelara.
- Pricing pressure in healthcare.
- Uncertainties from talc litigation.
- Regulatory and clinical risks.
- Valuation no longer attractive after the price recovery.
What we are watching
- Quarterly results and outlook on July 15, 2026.
- Product development Darzalex, Carvykti, Tremfya, Tecvayli and Talvey.
- Compensation for declining Stelara revenues.
- Growth in the MedTech business, particularly in cardiovascular and surgical technologies.
Summary
Johnson & Johnson continues to rank among the highest-quality healthcare companies worldwide. The diversified business model, stable cash flow generation, and strong innovation capabilities create a solid foundation for sustainable long-term growth. The combination of Innovative Medicine and MedTech reduces dependence on individual products and opens up multiple structural growth drivers.
With the acquisition of Firefly Bio, the company further strengthens its oncology pipeline and invests strategically in future technologies. Despite existing risks from patent expirations, regulatory pressure, and ongoing talc litigation, Johnson & Johnson has an exceptionally strong balance sheet and high financial flexibility. Together with its more than six-decade streak of continuous dividend increases, the company remains excellently positioned to create sustainable long-term value for its shareholders.
Rating According to the MUMAK Method
| Category | Rating |
|---|---|
| Geopolitics | Positive |
| Industry | Positive |
| Fundamentals | Positive |
| News & Sentiment | Positive |
| Technical Analysis | Positive |
